Company ups manufacturing investment in
Limerick by $1 billion; unveils new
$800 million Kinsale
facility
New investment will enhance global medicine
production, benefiting millions of patients worldwide
INDIANAPOLIS, Sept. 12,
2024 /PRNewswire/ -- Eli Lilly and Company
(NYSE: LLY) today announced a $1
billion expansion of its Limerick, Ireland, manufacturing site to increase
production of biologic active ingredients, including those for its
recently approved treatment for early symptomatic Alzheimer's
disease. The company also unveiled its new $800 million facility expansion in Kinsale,
Ireland, which began making
medicines last year to meet demand for Lilly's latest diabetes and
obesity treatments.
This additional investment is part of the most ambitious
manufacturing expansion agenda in the company's history. Since
2020, Lilly has committed more than $20
billion to build, expand and acquire manufacturing
facilities in the U.S. and Europe.
"These investments will boost the production of some of our
medicines, helping millions of people with diabetes, obesity and
Alzheimer's disease live the healthiest lives possible," said
Edgardo Hernandez, executive vice
president and president of Lilly Manufacturing Operations. "We
won't stop there – these state-of-the-art facilities will also be
equipped to support our promising pipeline molecules of the
future."
Limerick, Ireland
Once complete, Limerick will join Lilly's global manufacturing
network producing the biologic active ingredients for the company's
Alzheimer's disease portfolio and other biologic medicines.
"Alzheimer's disease is a devastating diagnosis for both the
patient and for their loved ones, along with having a huge burden
on society," said Anne E. White,
executive vice president and president of Lilly Neuroscience. "The
treatments we will make here in Limerick offer the potential to be
able to slow the progression of the disease and make life better
for millions of people around the world."
Today's announcement brings Lilly's total Limerick investment to
$2 billion, doubling the investment
the company announced in March 2023.
Advanced technologies such as machine learning, AI and automated
robotics and systems at the site will enable right-first-time
execution, all in support of the safe and reliable supply of
medicines. As a part of this expansion, Lilly will create another
150 jobs for highly skilled workers in Limerick such as engineers,
scientists, quality assurance professionals and operations
personnel, for a total of 450 employees. Lilly initially announced
the Limerick site in 2022 and broke ground in March 2023. Production of biologic active
ingredients for Lilly medicines is on track to start in 2026.
The Limerick investment project is subject to planning approval,
and the company will submit a planning application to the Limerick
City and County Council in due course.
Kinsale, Ireland
Lilly remains dedicated to addressing major global health issues,
and the Kinsale facility is pivotal to maintaining the safe and
reliable supply of Lilly's diabetes and obesity medications. The
official opening of Lilly's Kinsale manufacturing site expansion
marks the completion of the state-of-the-art project to help meet
the demand for current and future treatments. The site employs a
digital-first process that integrates continuous manufacturing
technology to create a new manufacturing platform for creating
complex peptides. This facility was recently recognized as the
winner of the Innovation category in the prestigious "Facility of
the Year" awards program run by the International Society of
Pharmaceutical Engineers.
Ireland's skilled workforce,
regulatory environment and pro-innovation government policies have
contributed to Lilly's nearly fifty-year presence in the country.
In parallel with our manufacturing growth, Lilly's Global Business
Solutions center in Cork has quadrupled employment levels
since 2019, with more than 2,000 employees expected by the end of
2024, over half of whom are working in clinical research and
development.
Sustainability
Lilly has a long-standing commitment to
sustainability and respecting the local environment, establishing
environmental programs across all sites in Ireland to monitor the quality of the
ambient air, the flora and fauna and the local marine habitat. Once
completed, the Limerick site will operate with 35% lower energy
intensity, use 40% less water, and generate 15% less waste than
traditional biopharmaceutical manufacturing processes. In Kinsale,
Lilly has the single largest privately owned solar farm – 26 acres
– in the Republic of Ireland,
which powers a significant portion of the facility.
About Lilly
Lilly is a medicine
company turning science into healing to make life better for
people around the world. We've been pioneering life-changing
discoveries for nearly 150 years, and today our medicines help more
than 51 million people across the globe. Harnessing the power of
biotechnology, chemistry and genetic medicine, our scientists are
urgently advancing new discoveries to solve some of the world's
most significant health challenges: redefining diabetes care;
treating obesity and curtailing its most devastating long-term
effects; advancing the fight against Alzheimer's disease; providing
solutions to some of the most debilitating immune system disorders;
and transforming the most difficult-to-treat cancers into
manageable diseases. With each step toward a healthier world, we're
motivated by one thing: making life better for millions more
people. That includes delivering innovative clinical trials that
reflect the diversity of our world and working to ensure our
medicines are accessible and affordable. To learn more, visit
Lilly.com and Lilly.com/news, or follow us on Facebook,
Instagram and LinkedIn. C-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about planned capital investments in manufacturing sites and
reflects Lilly's current beliefs and expectations. There are
substantial risks and uncertainties in the manufacturing process,
development, and commercialization of pharmaceutical products which
could impact the overall commercial success of our products. For
further discussion of risks and uncertainties relevant to Lilly's
business that could cause actual results to differ from Lilly's
expectations, see Lilly's Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.
Refer
to:
|
Carla Cox;
cox_carla@lilly.com; +1 317-750-3923
|
|
Joe Fletcher;
jfletcher@lilly.com; +1 317-296-2884
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-expands-manufacturing-footprint-in-ireland-with-1-8-billion-investment-302245823.html
SOURCE Eli Lilly and Company